Head-to-head · free
Accenture plc vs Exascale Labs
ACN vs XLAB — return on capital, cash generation, margins and balance sheet side by side.
ACN
5 / 5
measures where ACN leads
XLAB
0 / 5
measures where XLAB leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | ACN · FY2026 | XLAB · FY2026 |
|---|---|---|
| Revenue | $18.0B | $14.8M |
| Net income | $1.8B | (12.2M) |
| Revenue growth (yearly, multi-year) | 4.6% | — |
| Free cash flow | $11.6B | — |
| Free cash flow margin | 64.4% | — |
| Net cash / (debt) | — | — |
| ROIC | 20.8% | — |
| Return on equity | 25.8% | — |
| Gross margin | 31.9% | 15.8% |
| Operating margin | 14.7% | -43.4% |
| Net debt / EBITDA | -0.55x | 1.39x |
Figures are as reported by each company; latest fiscal year shown.
Where Accenture plc's cash went (FY2026)
- Capital spending
- $742.7M
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Where Exascale Labs's cash went (FY2026)
- Capital spending
- —
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free